Articles | Volume 10, issue 2
https://doi.org/10.5194/jbji-10-93-2025
© Author(s) 2025. This work is distributed under
the Creative Commons Attribution 4.0 License.
the Creative Commons Attribution 4.0 License.
https://doi.org/10.5194/jbji-10-93-2025
© Author(s) 2025. This work is distributed under
the Creative Commons Attribution 4.0 License.
the Creative Commons Attribution 4.0 License.
Original full-length article
| 
31 Mar 2025
Original full-length article |
| 31 Mar 2025
| 31 Mar 2025
Dalbavancin to facilitate early discharge in the treatment of complex musculoskeletal infections: a multi-centre real-life application
Tariq Azamgarhi
CORRESPONDING AUTHOR
Pharmacy Department, Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, HA7 4LP, United Kingdom
Simon Warren
Bone Infection Unit, Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, HA7 4LP, United Kingdom
Antonia Scobie
Bone Infection Unit, Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, HA7 4LP, United Kingdom
Natasha Karunaharan
Bone Infection Unit, Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, HA7 4LP, United Kingdom
Cristina Perez-Sanchez
Pharmacy Department, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Rebecca Houghton
Department of Microbiology, Hampshire Hospitals NHS Foundation Trust, Hampshire, Basingstoke, United Kingdom
Salma Hassan
Department of Microbiology, Hampshire Hospitals NHS Foundation Trust, Hampshire, Basingstoke, United Kingdom
Julie Lourtet-Hascoët
Infectious Diseases and Microbiology Department, Hôpital Joseph Ducuing, Toulouse, France
Clinical Microbiology Department, Hôpital Saint Joseph, Paris, France
Hannah Kershaw
Pharmacy Department, Royal Free Hospital NHS Foundation Trust, London, United Kingdom
Parham Sendi
Institute for Infectious Diseases, University of Bern, Bern, Switzerland
Kordo Saeed
Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
Related authors
Tariq Azamgarhi, Craig Gerrand, and Simon Warren
J. Bone Joint Infect., 10, 33–39, https://doi.org/10.5194/jbji-10-33-2025, https://doi.org/10.5194/jbji-10-33-2025, 2025
Short summary
Short summary
We explore optimising antibiotic use to prevent infections in endoprosthetic replacement for bone tumours. We found 26 % of infections were linked to initial surgery, with most due to secondary factors like wound complications. The main bacteria are Staphylococcus aureus and coagulase-negative staphylococci. Our findings suggest targeting these bacteria with prophylactic antibiotics and applying measures to prevent secondary infections to improve infection control in orthopaedic oncology.
Tariq Azamgarhi, Craig Gerrand, John A. Skinner, Alexander Sell, Robert A. McCulloch, and Simon Warren
J. Bone Joint Infect., 8, 219–227, https://doi.org/10.5194/jbji-8-219-2023, https://doi.org/10.5194/jbji-8-219-2023, 2023
Short summary
Short summary
We compared prosthetic joint infection (PJI) and acute kidney injury (AKI) rates among cohorts before and after changing our hospital's antimicrobial prophylaxis from cefuroxime to teicoplanin plus gentamicin for primary total joint arthroplasty. Switching to teicoplanin and gentamicin was associated with a significant risk reduction for PJI of 75.2 %. Significantly higher AKI rates were seen in patients receiving teicoplanin plus gentamicin; however, these were mild (KDIGO stage 1).
Tariq Azamgarhi and Simon Warren
J. Bone Joint Infect., 6, 47–50, https://doi.org/10.5194/jbji-6-47-2020, https://doi.org/10.5194/jbji-6-47-2020, 2020
Short summary
Short summary
We present the first reported case of prosthetic joint infection caused by Trueperella pyogenes. This animal pathogen rarely causes human infection. Our patient was successfully treated with single-stage exchange and 12 weeks of rifampicin and moxifloxacin.
Charlotte Smith, Robert J. Maloney, Deborah Wearmouth, Hemant Sharma, Kordo Saeed, Nusreen Ahmad-Saeed, Rachel Annett, Lucinda Barrett, Sara E. Boyd, Peter Davies, Harriet Hughes, Gwennan Jones, Laura Leach, Maureen Lynch, Deepa Nayar, Martin Marsh, Shanine Mitchell, Lynn Moffat, Luke S. P. Moore, Michael E. Murphy, Shaan Ashk O'Shea, Teresa Peach, Christina Petridou, Niamh Reidy, Ben Talbot, Catherine Aldridge, and Gavin Barlow
J. Bone Joint Infect., 10, 61–71, https://doi.org/10.5194/jbji-10-61-2025, https://doi.org/10.5194/jbji-10-61-2025, 2025
Short summary
Short summary
Urgent analysis of joint fluid is a common test in patients with possible septic arthritis (bacterial infection of a joint). One aspect of this test, called the Gram stain, is considered important clinically, but previous single hospital studies have suggested it will miss a considerable number of infections. This large multi-hospital UK study assessed this test and found that it will miss 73 % of infections, questioning its value. More research on rapid tests using new technologies is required.
Tariq Azamgarhi, Craig Gerrand, and Simon Warren
J. Bone Joint Infect., 10, 33–39, https://doi.org/10.5194/jbji-10-33-2025, https://doi.org/10.5194/jbji-10-33-2025, 2025
Short summary
Short summary
We explore optimising antibiotic use to prevent infections in endoprosthetic replacement for bone tumours. We found 26 % of infections were linked to initial surgery, with most due to secondary factors like wound complications. The main bacteria are Staphylococcus aureus and coagulase-negative staphylococci. Our findings suggest targeting these bacteria with prophylactic antibiotics and applying measures to prevent secondary infections to improve infection control in orthopaedic oncology.
Tom A. Yates, Olivier Vahesan, Simon Warren, and Antonia Scobie
J. Bone Joint Infect., 9, 217–223, https://doi.org/10.5194/jbji-9-217-2024, https://doi.org/10.5194/jbji-9-217-2024, 2024
Short summary
Short summary
Our orthopaedic hospital attempts to culture tuberculosis (TB) bacteria from all bone and joint samples sent to the microbiology laboratory. We looked at 6162 TB cultures performed between 2017 and 2022. Bacteria that cause TB, or similar bacteria, were found in 1 in every 229 patients. Tests were more likely to be positive in people being investigated for cancer (sarcoma) and in samples from the spine, whereas they were much less likely to be positive in samples taken from replacement joints.
Noémie Reinert, Katinka Wetzel, Fabian Franzeck, Mario Morgenstern, Markus Aschwanden, Thomas Wolff, Martin Clauss, and Parham Sendi
J. Bone Joint Infect., 9, 183–190, https://doi.org/10.5194/jbji-9-183-2024, https://doi.org/10.5194/jbji-9-183-2024, 2024
Short summary
Short summary
We assessed concordance of in-house guidelines for diagnostic principles and antibiotic treatment duration (ABT) 2 years after their implementation. The goal was to standardize diagnostic and treatment principles: are we doing what we recommend? The adherence to recommendations in terms of biopsy sampling was good, moderate for histopathology and poor for anatomic labeling. In terms of ABT duration, the adherence was good, but further shortening for surgically cured cases is necessary.
Stéphanie Pascual, Brooklyn Noble, Nusreen Ahmad-Saeed, Catherine Aldridge, Simone Ambretti, Sharon Amit, Rachel Annett, Shaan Ashk O'Shea, Anna Maria Barbui, Gavin Barlow, Lucinda Barrett, Mario Berth, Alessandro Bondi, Nicola Boran, Sara E. Boyd, Catarina Chaves, Martin Clauss, Peter Davies, Ileana T. Dianzo-Delgado, Jaime Esteban, Stefan Fuchs, Lennart Friis-Hansen, Daniel Goldenberger, Andrej Kraševac Glaser, Juha O. Groonroos, Ines Hoffmann, Tomer Hoffmann, Harriet Hughes, Marina Ivanova, Peter Jezek, Gwennan Jones, Zeynep Ceren Karahan, Cornelia Lass-Flörl, Frédéric Laurent, Laura Leach, Matilde Lee Horsbøll Pedersen, Caroline Loiez, Maureen Lynch, Robert J. Maloney, Martin Marsh, Olivia Milburn, Shanine Mitchell, Luke S. P. Moore, Lynn Moffat, Marianna Murdjeva, Michael E. Murphy, Deepa Nayar, Giacomo Nigrisoli, Fionnuala O'Sullivan, Büşra Öz, Teresa Peach, Christina Petridou, Mojgan Prinz, Mitja Rak, Niamh Reidy, Gian Maria Rossolini, Anne-Laure Roux, Patricia Ruiz-Garbajosa, Kordo Saeed, Llanos Salar-Vidal, Carlos Salas Venero, Mathyruban Selvaratnam, Eric Senneville, Peter Starzengruber, Ben Talbot, Vanessa Taylor, Rihard Trebše, Deborah Wearmouth, Birgit Willinger, Marjan Wouthuyzen-Bakker, Brianne Couturier, and Florence Allantaz
J. Bone Joint Infect., 9, 87–97, https://doi.org/10.5194/jbji-9-87-2024, https://doi.org/10.5194/jbji-9-87-2024, 2024
Short summary
Short summary
This study conducted in multiple sites across Europe aimed to evaluate the BIOFIRE Joint Infection (JI) Panel, a new technology that uses multiplex PCR to detect microorganisms in synovial fluid of patients with suspicion of joint infections in 1 h, in comparison with synovial fluid culture. Results showed an overall agreement of 85 % to 88.4 % between the two methods. The JI Panel detected additional organisms, and the positive user experience highlights its clinical significance.
Tariq Azamgarhi, Craig Gerrand, John A. Skinner, Alexander Sell, Robert A. McCulloch, and Simon Warren
J. Bone Joint Infect., 8, 219–227, https://doi.org/10.5194/jbji-8-219-2023, https://doi.org/10.5194/jbji-8-219-2023, 2023
Short summary
Short summary
We compared prosthetic joint infection (PJI) and acute kidney injury (AKI) rates among cohorts before and after changing our hospital's antimicrobial prophylaxis from cefuroxime to teicoplanin plus gentamicin for primary total joint arthroplasty. Switching to teicoplanin and gentamicin was associated with a significant risk reduction for PJI of 75.2 %. Significantly higher AKI rates were seen in patients receiving teicoplanin plus gentamicin; however, these were mild (KDIGO stage 1).
Christen Ravn, Jeroen Neyt, Natividad Benito, Miguel Araújo Abreu, Yvonne Achermann, Svetlana Bozhkova, Liselotte Coorevits, Matteo Carlo Ferrari, Karianne Wiger Gammelsrud, Ulf-Joachim Gerlach, Efthymia Giannitsioti, Martin Gottliebsen, Nis Pedersen Jørgensen, Tomislav Madjarevic, Leonard Marais, Aditya Menon, Dirk Jan Moojen, Markus Pääkkönen, Marko Pokorn, Daniel Pérez-Prieto, Nora Renz, Jesús Saavedra-Lozano, Marta Sabater-Martos, Parham Sendi, Staffan Tevell, Charles Vogely, Alex Soriano, and the SANJO guideline group
J. Bone Joint Infect., 8, 29–37, https://doi.org/10.5194/jbji-8-29-2023, https://doi.org/10.5194/jbji-8-29-2023, 2023
Short summary
Short summary
Management of septic arthritis in native joints (SANJO) is often conducted by clinicians of different specialties, experience levels, and at all hours of the day. The SANJO guideline group makes evidence-based recommendations for diagnosis, microbiological investigation, initial surgery, empirical antibiotic treatment, early mobilization, evaluation of outcomes, and treatment failure. Special considerations were made for children, tuberculosis, and SANJO after cruciate ligament reconstruction.
Simon Martin Heinrich, Parham Sendi, and Martin Clauss
J. Bone Joint Infect., 6, 423–424, https://doi.org/10.5194/jbji-6-423-2021, https://doi.org/10.5194/jbji-6-423-2021, 2021
Short summary
Short summary
We report on an 83-year-old woman who had an open removal of a baker's cyst several months after total knee arthroplasty. The following wound healing problem was first misinterpreted as being superficial. With an injection of methylene blue and a contrast medium, we showed the extent of the sinus tract, proving the periprosthetic joint infection.
Tariq Azamgarhi and Simon Warren
J. Bone Joint Infect., 6, 47–50, https://doi.org/10.5194/jbji-6-47-2020, https://doi.org/10.5194/jbji-6-47-2020, 2020
Short summary
Short summary
We present the first reported case of prosthetic joint infection caused by Trueperella pyogenes. This animal pathogen rarely causes human infection. Our patient was successfully treated with single-stage exchange and 12 weeks of rifampicin and moxifloxacin.
Cited articles
Azamgarhi, T., Shah, A., and Warren, S.: Clinical Experience of Implementing Oral Versus Intravenous Antibiotics (OVIVA) in a Specialist Orthopedic Hospital, Clin. Infect. Dis., 73, e2582–e2588, https://doi.org/10.1093/cid/ciaa985, 2021.
Buehrle, D. J., Shields, R. K., Shah, N., Shoff, C., and Sheridan, K.: Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users, Open Forum Infect. Dis., 23, ofx102, https://doi.org/10.1093/ofid/ofx102, 2017.
Chapman, A. L. N., Patel, S., Horner, C., Green, H., Guleri, A., Hedderwick, S., Snape, S., Statham, J., Wilson, E., Gilchrist, M., and Seaton, R. A.: Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK, JAC Antimicrob. Resist., 26, dlz026, https://doi.org/10.1093/jacamr/dlz026, 2019.
Dorr, M. B., Jabes, D., Cavaleri, M., Dowell, J., Mosconi, G., Malabarba, A., White, R. J., and Henkel, T. J.: Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide, J. Antimicrob. Chemother., 55, ii25–ii30, https://doi.org/10.1093/jac/dki008, 2005.
Dunne, M. W., Puttagunta, S., Sprenger, C. R., Rubino, C., Van Wart, S., and Baldassarre, J.: Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue, Antimicrob. Agents Chemother., 59, 1849–1855, https://doi.org/10.1128/AAC.04550-14, 2015.
Li, H.-K., Rombach, I., Zambellas, R., Walker, A. S., McNally, M. A., Atkins, B. L., Lipsky, B. A., Hughes, H. C., Bose, D., Kümin, M., Scarborough, C., Matthews, P. C., Brent, A. J., Lomas, J., Gundle, R., Rogers, M., Taylor, A., Angus, B., Byren, I., Berendt, A. R., Warren, S., Fitzgerald, F. E., Mack, D. J. F., Hopkins, S., Folb, J., Reynolds, H. E., Moore, E., Marshall, J., Jenkins, N., Moran, C. E., Woodhouse, A. F., Stafford, S., Seaton, R. A., Vallance, C., Hemsley, C. J., Bisnauthsing, K., Sandoe, J. A. T., Aggarwal, I., Ellis, S. C., Bunn, D. J., Sutherland, R. K., Barlow, G., Cooper, C., Geue, C., McMeekin, N., Briggs, A. H., Sendi, P., Khatamzas, E., Wangrangsimakul, T., Wong, T. H. N., Barrett, L. K., Alvand, A., Old, C. F., Bostock, J., Paul, J., Cooke, G., Thwaites, G. E., Bejon, P., and Scarborough, M.: Oral versus Intravenous Antibiotics for Bone and Joint Infection, New Engl. J. Med., 380, 425–436, https://doi.org/10.1056/nejmoa1710926, 2019.
Lovatti, S., Tiecco, G., Mulé, A., Rossi, L., Sforza, A., Salvi, M., Signorini, L., Castelli, F., and Quiros-Roldan, E.: Dalbavancin in Bone and Joint Infections: A Systematic Review, MDPI, https://doi.org/10.3390/ph16071005, 2023.
Rappo, U., Puttagunta, S., Shevchenko, V., Shevchenko, A., Jandourek, A., Gonzalez, P. L., Suen, A., Mas Casullo, V., Melnick, D., Miceli, R., Kovacevic, M., De Bock, G., and Dunne, M. W.: Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety, Open Forum Infect. Dis., 6, ofy331, https://doi.org/10.1093/ofid/ofy331, 2019.
Senneville, E., Cuervo, G., Gregoire, M., Hidalgo-Tenorio, C., Jehl, F., Miro, J. M., Seaton, A., Söderquist, B., Soriano, A., Thalhammer, F., and Pea, F.: Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel, Int. J. Antimicrob. Agents, 62, 106960, https://doi.org/10.1016/j.ijantimicag.2023.106960, 2023.
Zhang, R., Polenakovik, H., Barreras Beltran, I. A., Waalkes, A., Salipante, S. J., Xu, L., and Werth, B. J.: Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization, Clin. Infect. Dis., 75, 1641–1644, https://doi.org/10.1093/cid/ciac341, 2022.
Short summary
This study evaluates dalbavancin, an antibiotic with a long duration of action, in treating complex bone and joint infections. It does not require daily dosing, allowing patients to leave the hospital earlier and reducing costs. Dalbavancin is shown to be effective and safe, especially for patients unsuitable for oral antibiotics or outpatient therapy, achieving similar results to traditional treatments while cutting healthcare costs.
This study evaluates dalbavancin, an antibiotic with a long duration of action, in treating...
